TY  - JOUR
T1  - Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer
A1  - Filho, Marcos Aurélio Fonseca Magalhães
A1  - Jr., Pedro Nazareth Aguiar
A1  - Neves, Milena Brachmans Mascarenhas
A1  - Jr., Gilberto de Lima Lopes
A1  - Giglio, Auro del
Y1  - 2022/05/02/
KW  - Cost-benefit analysis
KW  - HER2-positive
KW  - Breast neoplasms
KW  - Ado-trastuzumab emtansine
KW  - Neoplasm
KW  - residual
PY  - 2022
DO  - 10.31744/einstein_journal/2022GS6655
JF  - einstein (São Paulo)
VL  - 20
SP  - 
EP  - 
LA  - en
SN  - 1679-4508
UR  - https://journal.einstein.br/article/cost-effectiveness-analysis-of-ado-trastuzumab-emtansine-for-the-treatment-of-residual-invasive-her2-positive-breast-cancer/
Y2  - 2026/08/12/04:35:16
ER  -